Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EBITDA: 2012-2024

Historic EBITDA for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $205.4 million.

  • Amphastar Pharmaceuticals' EBITDA fell 55.62% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.9 million, marking a year-over-year decrease of 30.02%. This contributed to the annual value of $205.4 million for FY2024, which is 4.28% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported EBITDA of $205.4 million as of FY2024, which was up 4.28% from $197.0 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' EBITDA ranged from a high of $205.4 million in FY2024 and a low of $11.0 million during FY2020.
  • Its 3-year average for EBITDA is $170.0 million, with a median of $197.0 million in 2023.
  • Data for Amphastar Pharmaceuticals' EBITDA shows a peak YoY soared of 28,187.18% (in 2020) over the last 5 years.
  • Over the past 5 years, Amphastar Pharmaceuticals' EBITDA (Yearly) stood at $11.0 million in 2020, then spiked by 538.00% to $69.9 million in 2021, then surged by 53.82% to $107.5 million in 2022, then soared by 83.25% to $197.0 million in 2023, then increased by 4.28% to $205.4 million in 2024.